7th Eurasian Hematology Oncology Summit

 

7th Eurasian Hematology Oncology Summit
A

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D-VTd Beneficial for PFS/OS in Transplant-Eligible Disease? Should We Use Thalidomide Maintenance After ASCT?

By 7th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
By 7th Eurasian Hematology Oncology Summit FEATURING Angelo Maiolino
141 views
December 9, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Myeloma
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With b…

Feat. E. Terpos
15:49
7th Eurasian Hematology Oncology Summit

2020 Updates on Maintenance Therapies in MM: Should We Consider Doub…

Feat. M. Gavriatopoulou
16:17
7th Eurasian Hematology Oncology Summit

VRd, KRd and IRd in R/R MM: Real World vs. Clinical Trial Data

Feat. A. Chari
14:20
7th Eurasian Hematology Oncology Summit

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D…

Feat. A. Maiolino